Strategic Agreement to Provide Silicon Nitride Spinal Interbody Fusion Devices
Amedica Corporation (Nasdaq:AMDA), a biomaterial company that has developed silicon nitride ceramics as a material platform to manufacture and commercialize orthopaedic implants, is pleased to announce that it has entered into a multi-year private labeling agreement with Spinal Kinetics, a leading innovator of advanced artificial spinal disc technology.
Pursuant to the terms of the non-exclusive agreement, Amedica will provide Spinal Kinetics with sterile packed silicon nitride spinal interbody fusion devices for sale in worldwide markets.
“We are very pleased with this alliance as it further validates the advantages of our proprietary silicon nitride biomaterial technology, and complements our current distribution structure,” said Dr. Sonny Bal, Chairman and CEO of Amedica Corporation. “We look forward to fostering this strategic partnership with Spinal Kinetics and believe that this agreement, along with others in the coming months and year, will fortify our position as the innovative leader of medical-grade silicon nitride products.”
Amedica’s spinal interbody fusion devices are made of a micro-composite silicon nitride biomaterial – a breakthrough ceramic with unmatched strength, durability and reliability. Its surface texture and hydrophilic nature attract both osteoblasts and physiologic proteins to ensure reliable osteointegration, while its surface biochemistry inhibits bacterial biofilm adhesion. This combination of optimal material properties is unique to Amedica’s silicon nitride material platform.
“The Spinal Kinetics team is very excited to add Amedica’s silicon nitride spinal fusion technology to our product portfolio,” said Tom Afzal, President and CEO of Spinal Kinetics. “This agreement is a critical additional step in broadening the range of uniquely innovative technologies we bring to the spine surgery community.”